What Wondermed does

Wondermed (legal entity WondermedAI) is a US-based precision mental healthcare company founded in 2020 and headquartered in Venice, California, that operates a telemedicine platform pairing patients nationwide with licensed physicians for psychedelic- and somatic-based treatment protocols. The company employs 11-50 people and serves patient segments including individuals with anxiety, depression, and chronic pain, with an explicit positioning around non-opioid alternatives for chronic pain and AI-assisted opioid tapering. It markets to patients via a waitlist, direct consumer acquisition and to clinicians through a sales-led provider-recruitment motion intended to convert practices into mental-health centers of excellence.

The company's core offering is Wondermed*AI*, an AI platform that integrates clinician prescribing data, patient experience data, and between-visit monitoring into a unified personalization layer using instruments such as PHQ-9 and GAD-7. On top of this core, the company markets three sub-products: Wonder AI Pharmacology (an AI system supporting medication selection, dosing, and duration for psychiatric pharmacotherapy), Wonder Relief (a 12-week virtual chronic-pain protocol combining low-dose ketamine with supplements, CBT, mindfulness, and coaching, with AI-assisted tapering and real-time safety alerts under the FDA 505(b)(2) pathway, NDA targeted 2030), and WonderFlow V2 (an anxiety/depression protocol built on flow-state neuroscience using proprietary Wonder Ketamine Lozenges and a daily supplement under the FDA 505(b)(2) pathway, NDA targeted 2031). Supporting proprietary assets include an AI abuse-surveillance system, adaptive dosing engines, and 1,500+ patient IRB-backed clinical data used to inform protocol refinement.

Wondermed generates revenue primarily through recurring telemedicine service subscriptions, distributed through its direct-to-consumer app and web platform as well as through a recruited provider network that delivers clinical care. GTM combines waitlist-based top-of-funnel demand capture with a provider-facing sales motion and clinical trial recruitment. Capital structure disclosure is limited: a single $4.6M funding round closed in June 2022 is the only event on record, no parent company, subsidiaries, or M&A activity is reported, and no regulatory actions against the company are noted. Academic institution partnerships support the FDA 505(b)(2) clinical development but the partner is unnamed in available sources.

Name

Wondermed

Legal name

WondermedAI

Website

https://wondermed.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Wondermed is a US-based telemedicine company offering AI-powered precision mental healthcare that pairs patients with physicians for psychedelic- and somatic-based protocols targeting anxiety, depression, and chronic pain via FDA 505(b)(2) pathway programs.

Ownership category

akta.pro rank

Product category

Digital Mental Healthcare / Telemedicine Psychiatry

NAICS

Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330), Offices of Physicians (except Mental Health Specialists) (621111)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

General Mental Health Therapy Platforms (Talk Therapy) (HLALAEAA)

akta.pro secondary industries

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), Healthcare & Wellness Personalization (HDAAAGAI)

Keywords

• Precision mental healthcare
• Ketamine telemedicine
• AI psychiatry platform
• Chronic pain treatment
• Psychedelic protocols

Headquarters

HQ city

Venice

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Telemedicine Services: Revenue generated from telemedicine-based mental healthcare services delivered to patients, including AI-guided protocols for anxiety, depression, and chronic pain conditions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Wondermed is a precision mental healthcare company that delivers AI-guided psychiatric and chronic pain treatment protocols via telemedicine. Its core offering combines proprietary ketamine-based therapies (Wonder Relief for chronic pain, WonderFlow for anxiety and depression) with the Wondermed AI platform that personalizes medication selection, dosing, and ongoing monitoring for each patient. Licensed clinicians deliver care remotely through the Wondermed app and web platform nationwide.

Product overview

Wondermed is a precision mental healthcare company offering a platform of AI-powered products. The core system is Wondermed AI, which connects prescribing data, patient experiences, and between-visit information to personalize care. Key products include Wonder AI Pharmacology for medication guidance, Wonder Relief for chronic pain management via ketamine protocol, and WonderFlow V2 for anxiety and depression treatment using flow-state neuroscience. Supporting offerings include proprietary Wonder Ketamine Lozenges and WonderFlow Daily Supplement. All products integrate AI personalization with clinical oversight, targeting FDA 505(b)(2) regulatory pathways.

Differentiator

Problem solved

Functional benefit

Brands

• Wondermed AI: AI platform connecting prescribing, patient experience, and between-visit data to personalize mental healthcare.
• Wonder AI Pharmacology
• Wonder Relief
• WonderFlow / WonderFlow V2

Products and services

• Wondermed AI Core AI platform that connects prescribing data, patient experiences, and between-visit information to personalize mental healthcare delivery to every patient. Includes adaptive dosing, real-time safety alerts, and AI abuse surveillance. Aimed at patients receiving mental healthcare through the Wondermed telemedicine service.
• Wonder AI Pharmacology AI-powered system supporting personalized psychiatric pharmacotherapy by guiding medication selection, dosing, and duration using patient response data. Designed for mental health patients seeking precision medication management.
• Wonder Relief 12-week virtual protocol providing a safer non-opioid alternative for chronic pain management. Combines low-dose ketamine, supplements, CBT, mindfulness, and coaching with AI-assisted opioid tapering and real-time safety monitoring. Aimed at patients with chronic pain conditions seeking alternatives to opioid therapy.
• WonderFlow V2 AI-guided protocol for anxiety and depression built on flow state neuroscience. Incorporates Wonder Ketamine Lozenges, WonderFlow Daily Supplement, and adaptive AI personalization for dosing and intervention pathways. Designed for patients with anxiety and depression seeking psychedelic-assisted treatment.
• Wonder Ketamine Lozenges Proprietary ketamine formulation (100-400mg) paired with cannabinoids, administered 4-8x monthly as a neuromodulatory primer for flow-state induction. Used within the WonderFlow V2 protocol for anxiety and depression patients.
• WonderFlow Daily Supplement Daily organic supplement featuring functional mushrooms and botanicals designed to support neuroplasticity, recovery, and treatment continuity as part of the WonderFlow protocol.

Quantifiable outcome

• Validated from 1,500+ patients with IRB-backed clinical data

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

One partnership is on record.

• Leading Academic Partner (Unnamed)coreStrategic or Co-development PartnerWondermed has established partnerships with leading academic institutions to support its FDA 505(b)(2) pathway clinical development programs for Wonder Relief (chronic pain) and WonderFlow V2 (anxiety and depression). These academic partnerships provide clinical research expertise and institutional oversight for the company's regulatory development programs.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• K Health: AI-powered telehealth platform combining chatbot triage with clinician visits for primary care and mental health. Comparable to Wondermed's AI-first clinical decision-support approach layered on top of telemedicine delivery.
• Compass Pathways: Clinical-stage psychedelic therapy developer (psilocybin) pursuing FDA approval for treatment-resistant depression. Comparable to Wondermed in pursuing regulated, FDA-pathway psychedelic/ketamine therapies for mental-health indications.
• Field Trip Health: Psychedelic-assisted therapy provider operating ketamine clinics for depression and related conditions. Comparable to Wondermed's use of ketamine protocols in mental-health treatment, though delivered in clinic rather than virtual.

Broad incumbents

• Talkspace: Public telepsychiatry and online therapy platform serving consumers, employers, and payers. Comparable to Wondermed for online talk therapy plus psychiatric medication management via subscription.
• Hims & Hers Health: Large-scale D2C telehealth platform spanning mental health, dermatology, and primary care with subscription prescribing. Overlaps with Wondermed on subscription telepsychiatry and AI-supported clinical workflows, though at vastly greater scale and category breadth.
• Lyra Health: Enterprise mental-health benefit platform offering therapy, coaching, and medication management to employees via employers. Comparable to Wondermed's B2B/provider-network GTM orientation and AI-augmented mental-healthcare delivery.
• BetterHelp: Largest direct-to-consumer online therapy subscription service. Comparable to Wondermed as a high-volume subscription tele-mental-health platform, though BetterHelp focuses on talk therapy rather than AI-guided pharmacotherapy.
• Spring Health: Enterprise mental-health platform combining therapy, coaching, and medication management with a precision-matching engine. Comparable to Wondermed's AI-personalization philosophy and outcomes-driven mental-healthcare positioning.

Direct peers

• Cerebral: Direct-to-consumer telemedicine platform for anxiety, depression, and ADHD with medication management. Comparable to Wondermed in offering AI-/clinician-supported psychiatric prescribing via a subscription telehealth model serving U.S. patients.
• Mindbloom: At-home ketamine therapy provider for depression and anxiety with guided protocols and clinician oversight. Most direct functional peer to Wondermed's WonderFlow/Wonder Relief ketamine-based mental-health and chronic-pain protocols.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wondermedai
• Instagraminstagram.com/wondermed_ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wondermed